BioCurate announces expansion of board and investment committee

Latest News

BioCurate, an independently operated joint venture between the University of Melbourne and Monash University, and with support of the Victorian State Government, has announced two new appointments.

Dr Marie Lindner has been appointed an independent director on the BioCurate Board and a member of its investment committee. Josephine Wu has been appointed an independent member of the investment committee.

Dr Lindner has worked in executive roles in pharmaceutical, biotech, venture capital, start-up and medtech companies with experience across therapeutic areas and modalities for over 30 years. This has included working in business and clinical development at several medium-large biotech and pharma companies, such as Novartis Pharmaceuticals, co-founding two startups, being a partner at a startup biotech VC group, and playing a senior role in a cell therapy company.

She also has experience as a practising clinician, having been a board-certified doctor specialising in internal medicine and clinical nutrition at the Hospital of the University of Pennsylvania and the Children's Hospital of Philadelphia.

“I am delighted to bring my global experience to support this innovative Melbourne venture succeed in the development of novel therapeutics, and to highlight to the world the exciting combination of pairing high-quality medical research with the capability of BioCurate's world-class team,” said Dr Lindner.

Josephine Wu has over 19 years of hedge fund, family office and global asset management experience including over 10 years of listed, pre-IPO and early-stage Pan-Asia healthcare investment experience. She is the founder and current CIO of Aionious Capital, a healthcare investment company that invests and provides business development and commercialisation strategies in the pan-Asia region, specifically in China.

“Australian universities are renowned for their high-quality research. With that, I am excited to apply my specialised global investment experience and knowledge to help commercialise this research into products that will be available to patients around the world,” she said.